1			CUSTOMER NUMBER 25268
2	IN THE UNITED STATES PATENT AND TRADEMARK OFFICE		
3 4	Applicants:	Call et al.	Attorney Docket No. MESO0070
5	Serial No.:	10/791,189	Group Art Unit: 1743
6	Filed:	March 1, 2004	Examiner: Douglas, Katherine L.
7			Confirmation No. 3193
8	Title:	BIOLOGICAL AI	.ARM
9		<u>INFORM</u>	IATION DISCLOSURE STATEMENT
1			Bellevue, Washington 98004
2			September 11, 2006
3	TO THE COMMISSIONER FOR PATENTS:		
4	Applicant is aware of the information listed in the attached form that may be material to the		
15	prosecution of the above-identified patent application.		
16	<u>X</u> 1.	Copies of the listed I the Examiner's use.	Foreign Patent Documents and Other Information are enclosed for
18 19 20	2.	or submitted to the	atents, publications, and other information were previously cited by U.S. Patent and Trademark Office in prior application Serial, and relied upon for an earlier filing date under 35 U.S.C. § 120.
21 22 23	3.	application relied upo	in marked with an "**" have not previously been cited in a priority on herein for an earlier filing date. Copies of any so-noted Foreign of Other Information are enclosed for the Examiner's use.
24 25	4.	the English language	on of the relevance of document I.D. No (which is not in e), as presently understood by the individual designated under 37 t knowledgeable about its content, is provided
26 27 28	5.	within three months of the date of entry of the	R. § 1.97(b), this information disclosure statement is being filed of the filing date of the national application, within three months of the national stage as set forth in 37 C.F.R. § 1.491 in an international the mailing date of a first Office Action on the merits.
29 30 31	6.		<u>CE</u> : Pursuant to 37 C.F.R. § 1.114, this information disclosure abmitted concurrently with a Request for Continued Examination

LAW OFFICES OF RONALD M. ANDERSON 600 - 108th Avenue N.E., Suite 507 Bellevue, Washington 98004 Telephone: (425) 688-8816 Fax: (425) 646-6314

1		(RCE) in the above-identified application.	
2	X 7.	Pursuant to 37 C.F.R. § 1.97(c), this information disclosure statement is being filed	
3		after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of either a	
4		final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, and is accompanied by:	
5	a.	a certification as specified in 37 C.F.R. § 1.97(e) (see below); or	
6 7	b.	X the fee set forth in 37 C.F.R. § 1.17(p). Please charge any additional fees to Deposit Account No. 01-1940.	
8	8.	Pursuant to 37 C.F.R. § 1.97(d), this information disclosure statement is being filed after the mailing date of either:	
10	a.	a final action under 37 C.F.R. § 1.113; or	
11	b.	a notice of allowance under 37 C.F.R. § 1.311,	
12		but before payment of the issue fee. The statement is accompanied by a	
13		certification as specified in 37 C.F.R. § 1.97(e), a statement requesting	
14 15		consideration of the information disclosure statement, and the petition fee set forth in 37 C.F.R. § 1.17(p). Check No in the amount of is enclosed.	
16	V 0		
17	X 9.	Electronic Filing Authorization to Charge Deposit Account: Please charge any additional fees or credit any overpayment to Deposit Account No. 01-1940.	
18			
19			
20		Respectfully submitted,	
21			
22		/mike king/	
23		Michael C. King	
24		Registration No. 44,832	
25			
26			
27			
28			
29			
30			
31			